Production (Stage)
Gain Therapeutics, Inc.
GANX
$1.73
-$0.07-3.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.22% | 16.00% | 44.91% | -102.86% | 15.03% |
| Total Depreciation and Amortization | 4.30% | -3.13% | 0.00% | 12.94% | -26.72% |
| Total Amortization of Deferred Charges | -8.33% | 0.00% | 9.09% | -8.33% | 0.00% |
| Total Other Non-Cash Items | -42.07% | 191.51% | -76.21% | 13,675.26% | -102.31% |
| Change in Net Operating Assets | 125.57% | 67.75% | -283.50% | 151.75% | 130.22% |
| Cash from Operations | -10.62% | 43.15% | -5.56% | -60.50% | 36.64% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -32.96% | -3.92% |
| Cash from Investing | -- | -- | -100.00% | -33.68% | -3.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 2.63% | 1.30% | -4.52% | 3.49% | -1.33% |
| Issuance of Common Stock | 3.58% | 180.79% | -91.73% | 6,270.17% | -98.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | 3.64% | 185.99% | -91.94% | 6,983.68% | -101.53% |
| Foreign Exchange rate Adjustments | 122.78% | -225.55% | 2,822.14% | 102.96% | -191.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.06% | 65.90% | -177.59% | 644.53% | -115.36% |